Thromb Haemost 2009; 101(04): 706-713
DOI: 10.1160/TH08-09-0611
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Relation of circulating matrix Gla-protein and anticoagulation status in patients with aortic valve calcification

Ralf Koos
1   Department of Cardiology, Medical Faculty, RWTH Aachen University, Aachen, Germany
,
Thilo Krueger
2   Department of Nephrology and Clinical Immunology, Medical Faculty, RWTH Aachen University, Aachen, Germany
,
Ralf Westenfeld
1   Department of Cardiology, Medical Faculty, RWTH Aachen University, Aachen, Germany
,
Harald Peter Kühl
1   Department of Cardiology, Medical Faculty, RWTH Aachen University, Aachen, Germany
,
Vincent Brandenburg
2   Department of Nephrology and Clinical Immunology, Medical Faculty, RWTH Aachen University, Aachen, Germany
,
Andreas Horst Mahnken
3   Department of Diagnostic Radiology, Medical Faculty, RWTH Aachen University, Aachen, Germany
,
Sven Stanzel
4   Institute of Medical Statistics, Medical Faculty, RWTH Aachen University, Aachen, Germany
,
Cees Vermeer
5   VitaK and Cardiovascular Research Institute CARIM, Maastricht University, Maastricht, The Netherlands
,
Ellen C. M. Cranenburg
5   VitaK and Cardiovascular Research Institute CARIM, Maastricht University, Maastricht, The Netherlands
,
Jürgen Floege
2   Department of Nephrology and Clinical Immunology, Medical Faculty, RWTH Aachen University, Aachen, Germany
,
Malte Kelm
1   Department of Cardiology, Medical Faculty, RWTH Aachen University, Aachen, Germany
,
Leon J. Schurgers
5   VitaK and Cardiovascular Research Institute CARIM, Maastricht University, Maastricht, The Netherlands
› Author Affiliations
Further Information

Publication History

Received: 22 September 2008

Accepted after major revision: 01 January 2009

Publication Date:
23 November 2017 (online)

Summary

Matrix-Gla Protein (MGP) is a vitamin K-dependent protein acting as a local inhibitor of vascular calcification. Vitamin K-antagonists (oral anticoagulant; OAC) inhibit the activation of MGP by blocking vitamin K-metabolism. The aim of this study was to investigate the effect of long-term OAC treatment on circulating MGP levels in humans and on MGP expression in mice. Additionally, we tested the association between circulating inactive MGP (ucMGP) levels and the presence and severity of AVC in patients with aortic valve disease (AVD). We analysed circulating ucMGP levels in 191 consecutive patients with echocardiographically proven calcific AVD and 35 control subjects. The extent of AVC in the patients was assessed by multislice spiral computed tomography. Circulating ucMGP levels were significantly lower in patients with AVD (348.6 ± 123.1 nM) compared to the control group (571.6 ± 153.9 nM, p < 0.001). Testing the effect of coumarin in mice revealed that also the mRNA expression of MGP in the aorta was downregulated. Multifactorial analysis revealed a significant effect of glomerular filtration rate and long-term OAC therapy on circulating ucMGP levels in the patient group. Subsequently, patients on long-term OAC had significantly increased AVC scores. In conclusion, patients with calcific AVD had significantly lower levels of circulating ucMGP as compared to a reference population, free of coronary and valvular calcifications. In addition, our data suggest that OAC treatment may decrease local expression of MGP, resulting in decreased circulating MGP levels and subsequently increased aortic valve calcifications as an adverse side effect.